THERACLION’S Echopulse® new clinical data to be presented during RSNA by the University of Virginia
• University of Virginia will present at Radiological Society of North America (RSNA) its latest U.S. clinical data for breast fibroadenomas
• Echotherapy is a safe and efficacious treatment option for breast fibroadenoma.
• Results suggest positive outcome of the ongoing pivotal trial of Echopulse® for non-invasive treatment of breast fibroadenomas.
THERACLION today announced the presentation of data from the U.S. pilot trial of echotherapy with Echopulse®, a non-invasive treatment using ultrasound-guided high-intensity focused ultrasound (HIFU), in women with breast fibroadenomas. Results will be presented at the Radiological Society of North America (RSNA) Annual Meeting that will be held from November 26 to December 1, 2017, at the McCormick Place in Chicago (USA). Theraclion also announced its participation to the RSNA as an exhibitor to present the Echopulse® system on booth #4475 in the French Pavilion.